Accomplished biopharmaceutical executive brings more than 25 years of experience leading vaccine and antibody product development for infectious disease indications

Dr. Nabors representing Appili at the World Vaccine Congress in Washington, D.C.

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer. Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones.

“Dr. Nabors brings an exceptional wealth of experience and established results to Appili, and he will play a critical role in advancing our programs and our business,” said Dr. Don Cilla, President and Chief Executive Officer of Appili Therapeutics. “Gary’s expertise in infectious disease will be instrumental in driving forward the development of our programs; ATI-1701, a vaccine for tularemia being funded by the U.S. Government through IND submission and ATI-1801, a treatment for cutaneous leishmaniasis (CL), a disfiguring infection of the skin. Both programs we believe may be eligible to receive FDA Priority Review Voucher (“PRV”) upon approval and his leadership in progressing candidates through these next crucial stages will be instrumental to our growth.”

Dr. Nabors joins Appili from Integrated BioTherapeutics Inc. (IBT) where, in his role as Executive Vice President and Chief Development Officer, he was responsible for leading the company’s vaccine and immunotherapeutic candidates through bioanalytical development, IND-enabling studies, GMP manufacturing and into clinical studies. Prior to that he served as President of DynPort Vaccine Company Inc. (a subsidiary of General Dynamics) where he was responsible for the overall success of the company, overseeing P&L responsibility and 800 staff, and establishing the technical, strategic, and regulatory direction for all projects in the company’s portfolio.

Over his accomplished 25-year career, Dr. Nabors has also held progressively senior roles with Sanofi Pasteur, Emergent BioSolutions, and the National Biodefense Analysis and Countermeasures Center (NBACC) within the U.S. Department of Homeland Security. He has played a central role in product development from pre-clinical stages through to Phase 3, for development of vaccines and therapeutics for pediatric, adult, and biodefense markets. He has also managed corporate subsidiaries of 120 employees, served on executive-level management committees and presented before Food and Drug Administration (FDA) advisory committees.

“The work being done in anti-infectives at Appili is important and I am eager to help further establish us as a key player in the fight against infection,” said Dr Nabors.

Dr. Nabors will be representing Appili at the World Vaccine Congress, the premier event for R&D and strategic partnering for the global vaccine industry, in Washington, D.C., from April 3rd to 6th, 2023. Dr. Nabors will be participating in scientific sessions to identify current trends in vaccine development and to network with key contacts that Appili may be able to work with to help advance its programs.

"The World Vaccine Congress provides a great opportunity to learn how others are progressing their vaccine development programs, and to have the opportunity to meet with key leaders in the industry," added Dr. Nabors. "I am looking forward to bringing this knowledge back to Appili to help us continue driving our pipeline forward.”

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

Forward looking statements

This news release contains “forward-looking statements”, including with respect to potential PRV eligibility for ATI-1701 and ATI-1801.e. Wherever possible, words such as “may “, “would”, “could “, “should”, “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those risks listed in the annual information form of the Company dated June 29, 2022 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230401005043/en/